Eli Lilly Drug Retatrutide Doubles Weight Loss vs Ozempic in Trial
The company reports that its triple-G drug retatrutide led to significantly more weight loss than Novo Nordisk's Ozempic in a head-to-head trial.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
2 publishers have covered this in 2 articles since 28 Oct 2026. STAT published first, on 28 October at 10:45 UTC; All Content from Business Insider followed 0 min later. The most recent article, from All Content from Business Insider, appeared on 28 October at 10:45 UTC.
Outlets reporting it: STAT, All Content from Business Insider.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Eli Lilly
- Novo Nordisk